KR102180223B1 - Anti-obesity composition comprising extract of Sargassum horneri - Google Patents
Anti-obesity composition comprising extract of Sargassum horneri Download PDFInfo
- Publication number
- KR102180223B1 KR102180223B1 KR1020190000353A KR20190000353A KR102180223B1 KR 102180223 B1 KR102180223 B1 KR 102180223B1 KR 1020190000353 A KR1020190000353 A KR 1020190000353A KR 20190000353 A KR20190000353 A KR 20190000353A KR 102180223 B1 KR102180223 B1 KR 102180223B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- obesity
- composition
- sargassum horneri
- hoesaengi
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 111
- 230000003579 anti-obesity Effects 0.000 title claims abstract description 58
- 239000000203 mixture Substances 0.000 title claims abstract description 54
- 241001260874 Sargassum horneri Species 0.000 title claims abstract description 34
- 230000000694 effects Effects 0.000 claims abstract description 52
- 210000001789 adipocyte Anatomy 0.000 claims abstract description 39
- 208000008589 Obesity Diseases 0.000 claims abstract description 27
- 235000020824 obesity Nutrition 0.000 claims abstract description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- 235000013305 food Nutrition 0.000 claims abstract description 13
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 11
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 102000040945 Transcription factor Human genes 0.000 claims description 14
- 108091023040 Transcription factor Proteins 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 9
- 230000002293 adipogenic effect Effects 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 6
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 claims description 5
- 241001279838 Pachysandra terminalis Species 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 241001453758 Lepisorus thunbergianus Species 0.000 claims description 2
- 241001146192 Ligularia stenocephala Species 0.000 claims description 2
- 241000476395 Indigofera bungeana Species 0.000 claims 1
- 241001409321 Siraitia grosvenorii Species 0.000 claims 1
- 230000004069 differentiation Effects 0.000 abstract description 14
- 238000004519 manufacturing process Methods 0.000 abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 201000010099 disease Diseases 0.000 description 16
- 239000000469 ethanolic extract Substances 0.000 description 13
- 150000003626 triacylglycerols Chemical class 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 11
- 241001474374 Blennius Species 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 239000000463 material Substances 0.000 description 9
- 235000013399 edible fruits Nutrition 0.000 description 8
- 235000013376 functional food Nutrition 0.000 description 8
- 241000186000 Bifidobacterium Species 0.000 description 7
- 235000019197 fats Nutrition 0.000 description 7
- 210000004209 hair Anatomy 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 235000019629 palatability Nutrition 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 241000186660 Lactobacillus Species 0.000 description 4
- 244000199866 Lactobacillus casei Species 0.000 description 4
- 235000013958 Lactobacillus casei Nutrition 0.000 description 4
- 241000687698 Monophylla Species 0.000 description 4
- 244000185386 Thladiantha grosvenorii Species 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 235000013325 dietary fiber Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 229940017800 lactobacillus casei Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 235000021067 refined food Nutrition 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 241000194031 Enterococcus faecium Species 0.000 description 3
- 240000001046 Lactobacillus acidophilus Species 0.000 description 3
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 3
- 241001468191 Lactobacillus kefiri Species 0.000 description 3
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000005445 natural material Substances 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 235000015277 pork Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 description 2
- 241000186012 Bifidobacterium breve Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241001573881 Corolla Species 0.000 description 2
- 241000194032 Enterococcus faecalis Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 241000194038 Lactococcus plantarum Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 244000070406 Malus silvestris Species 0.000 description 2
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 2
- 241000199919 Phaeophyceae Species 0.000 description 2
- 240000005809 Prunus persica Species 0.000 description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 235000013334 alcoholic beverage Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 235000021016 apples Nutrition 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229940032049 enterococcus faecalis Drugs 0.000 description 2
- 150000002148 esters Chemical group 0.000 description 2
- 235000021107 fermented food Nutrition 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000013324 preserved food Nutrition 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- WAPPRYMYMNVAFR-UHFFFAOYSA-N 2-sulfanylethanol Chemical compound OCCS.OCCS WAPPRYMYMNVAFR-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 102000014777 Adipokines Human genes 0.000 description 1
- 108010078606 Adipokines Proteins 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 241000186148 Bifidobacterium pseudolongum Species 0.000 description 1
- 102100034798 CCAAT/enhancer-binding protein beta Human genes 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 241000737241 Cocos Species 0.000 description 1
- 241001149724 Cololabis adocetus Species 0.000 description 1
- 208000000151 Colon Diverticulum Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- 240000001980 Cucurbita pepo Species 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241001058146 Erium Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000945963 Homo sapiens CCAAT/enhancer-binding protein beta Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 1
- 241000186679 Lactobacillus buchneri Species 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 240000002605 Lactobacillus helveticus Species 0.000 description 1
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- 241000194037 Lactococcus raffinolactis Species 0.000 description 1
- 241000192129 Leuconostoc lactis Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 108010074436 Sterol Regulatory Element Binding Protein 1 Proteins 0.000 description 1
- 102100026839 Sterol regulatory element-binding protein 1 Human genes 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000478 adipokine Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 238000013542 behavioral therapy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000020299 breve Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 231100001010 corrosive Toxicity 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 235000021038 drupes Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- -1 ethanol and methanol Chemical compound 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000003864 humus Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910001411 inorganic cation Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 229940054346 lactobacillus helveticus Drugs 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 235000015108 pies Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000012434 pretzels Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000012151 protein quantification reagent Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 235000019992 sake Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000020083 shōchū Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000019511 tuna Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 235000015041 whisky Nutrition 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/202—Algae extracts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 본 발명은 항비만 효과를 나타내는 괭생이 모자반 추출물(Sargassum horneri) 또는 그의 분획물을 포함하는 비만 예방 및 완화용 식품 조성물 또는 약학 조성물에 관한 것으로, 본 발명의 괭생이 모자반 추출물 또는 이로부터 분리한 분획물은 지방 세포 분화, 지방전구세포 형성 및 트리글리세리드(triglyceride)의 생성을 감소시키는 것이다.The present invention relates to a food composition or pharmaceutical composition for preventing and alleviating obesity, including the extract of Sargassum horneri or a fraction thereof, which exhibits anti-obesity effect, and the extract of the present invention, or isolated from One fraction is to reduce adipocyte differentiation, adipocyte formation and triglyceride production.
Description
본 발명은 괭생이 모자반 추출물을 유효성분으로 포함하는 항비만용 조성물에 관한 것으로, 보다 구체적으로 본 발명은 지방전구세포 형성과 트리글리세리드(triglyceride)의 생성을 감소하여 항비만 효과를 나타내는 괭생이 모자반 추출물 또는 그의 분획물을 포함하는 항비만용 조성물에 관한 것이다.The present invention relates to a composition for anti-obesity comprising an extract of hoesaengi chinensis as an active ingredient, and more specifically, the present invention reduces the formation of adipocytes and production of triglycerides, thereby showing an anti-obesity effect. Or it relates to a composition for anti-obesity comprising a fraction thereof.
비만(obesity)은 과다한 열량 섭취와 운동부족이 주된 원인이지만 그 외에도 사회적, 유전적, 환경적인 요인 등이 영향을 미치는 복합증후군으로, 음식의 섭취 량과 에너지 소비의 불균형에서 생기는 과잉의 에너지가 지방조직에서 중성지방 으로 축적되면서 발생하는 질병이며, 전 세계적으로 유병률이 크게 증가하고 있는 실정이다.Obesity is a complex syndrome that is mainly caused by excessive caloric intake and lack of exercise, but other social, genetic, and environmental factors affect it. Excess energy resulting from the imbalance between food intake and energy consumption is fat. It is a disease caused by accumulation of triglycerides in tissues, and the prevalence rate is increasing significantly worldwide.
비만은 그 자체가 갖는 문제점뿐만 아니라 당뇨, 심혈관질환, 고혈압, 고지혈증 같은 심각한 성인병을 유발할 수 있으며, 각종 암의 유병률을 높이기 때문에 치료에 많은 관심이 모이고 있다.Obesity, as well as its own problems, can cause serious adult diseases such as diabetes, cardiovascular disease, high blood pressure, and hyperlipidemia, and since it increases the prevalence of various cancers, there is a lot of interest in treatment.
세계보건기구(WHO)에서는 비만인구가 증가함에 따라 비만을 치료해야 할 질병으로 인식하여 세계적인 영양문제로 다루고 있다.The World Health Organization (WHO) recognizes obesity as a disease that needs to be treated as the number of obese population increases, and is treated as a global nutrition problem.
비만을 개선하기 위한 방법으로는 외과적 치료 외에 운동요법, 식사요법, 행동요법 그리고 식용 억제제, 설사제 또는 포만감을 주기 위한 섬유질 등을 사용하는 약물요법 등이 현재 알려져 있다. 최근에는 비만 치료를 위한 약물 치료제 개발 연구가 진행되고 있지만, 현재까지 개발된 약물치료제는 효능에 비해 두통, 불면증, 신경불안, 고혈압, 복통, 복부팽만, 배변 증가 등의 부작용이 있는 것으로 알려져 있다.As a method for improving obesity, in addition to surgical treatment, exercise therapy, diet therapy, behavior therapy, and drug therapy using dietary inhibitors, laxatives or fiber to give a feeling of fullness are currently known. In recent years, research on drug therapy development for the treatment of obesity is in progress, but the drug therapy developed so far is known to have side effects such as headache, insomnia, nervous anxiety, high blood pressure, abdominal pain, abdominal distention, and increased bowel movement compared to its efficacy.
이러한 약물 치료의 부작용으로 인해 새로운 항비만 기능성 식품 및 의약품 개발이 요구되고 있으며, 최근에는 천연물소재에서 비만 예방 및 개선에 효과적인 기능성 소재들을 찾아내고 작용 기전을 밝히는 연구 및 개발이 이루어지고 있다.Due to the side effects of such drug treatment, the development of new anti-obesity functional foods and pharmaceuticals is required, and in recent years, research and development to find functional materials effective in preventing and improving obesity from natural materials and revealing the mechanism of action have been conducted.
이와 관련하여 지방세포를 사용한 연구가 활발히 이루어지고 있다. 섭취한 영양소는 중성지방의 형태로 지방 조직에 출적되며, 비만은 지방세포의 비대와 과형성으로 인해 초래된다. 지방세포 연구는 지방 축적을 감소시키고 지방세포의 수를 줄이는 방안을 찾아내는 것이 핵심이다.In this regard, research using adipocytes is being actively conducted. Ingested nutrients are released in adipose tissue in the form of triglycerides, and obesity is caused by the hypertrophy and hyperplasia of fat cells. Adipocyte research is key to finding ways to reduce fat accumulation and reduce the number of fat cells.
이러한 연구에서 사용될 수 있는 모델로 제시된 것이 3T3-L1 지방전구세포이다. 상기 3T3-L1 지방전구세포는 지방세포로 분화될 수 있는 위임 줄기세포(committed stem cell)로 배지에 우태아혈청과 함께 IBMX(3-isobutyl-1-methylxanthine), dexamethasone(덱사메타손), insulin(인슐린)을 첨가하여 배양하면 지방세포로 분화되어 세포내 지방 축적을 관찰할 수 있다.3T3-L1 adipocytes are suggested as a model that can be used in this study. The 3T3-L1 adipocytes are committed stem cells that can be differentiated into adipocytes.IBMX (3-isobutyl-1-methylxanthine), dexamethasone (dexamethasone), insulin (insulin ) Is added and cultured to differentiate into adipocytes and the accumulation of fat within the cells can be observed.
한편, 최근 해조류가 줄 수 있는 영양학적 이익을 재조명하면서 그의 추출물 들을 이용하여 다양한 기능성 식품 소재들을 개발하기 위한 연구가 활발히 진행되고 있다. 해조류에는 수용성 식이섬유가 풍부하여 장 점막을 손상시키지 않고 배 변에 도움을 주므로 대장 게실증과 대장암 발병율을 낮추는 식품 소재로 알려져 있다. 또한 현대인들에게 부족하기 쉬운 무기 양이온들이 풍부하여 균형잡힌 영양 상태의 유지에도 도움을 주며 콜레스테롤이나 당의 흡수를 저하시켜 만성퇴 행성 질환의 개선에도 유리한 측면이 있는 것으로 보고되고 있다.Meanwhile, research to develop various functional food materials using its extracts is being actively conducted while re-examining the nutritional benefits that seaweed can provide. Since seaweed is rich in water-soluble dietary fiber, it does not damage the intestinal mucosa and helps bowel movements, so it is known as a food material that lowers the incidence of colon diverticulum and colon cancer. In addition, it is reported that there is an abundance of inorganic cations that are easy to lack in modern people, helping to maintain a balanced nutritional state, and lowering the absorption of cholesterol and sugar, which is also beneficial for improving chronic degenerative diseases.
최근들어 해조류로부터 추출한 다당류들이 항암작용과 면역활성을 갖는 것으로 보고되어, 식용으로뿐 아니라 기능성 식품 소재로서 해조류의 활용 점위는 확대될 것으로 추측된다.In recent years, polysaccharides extracted from seaweed have been reported to have anticancer and immune activity, and it is expected that the use of seaweed as a functional food material as well as edible will expand.
해조류 중 지금까지 주로 연구되어 온 소재는 미역, 다시마를 비롯하여 톳과 청각 등 예로부터 널리 부 식의 재료로 사용해 오던 해조류 들이었으나 최근 모자반의 배변효과와 지방 및 당의 배설효과에 대한 연구가 진행되어 활용가치를 탐색 중에 있다.Among the seaweeds, the materials that have been mainly studied up to now were seaweeds, kelp, and seaweeds that have been widely used for corrosives such as tot and hearing, but recently studies have been conducted on the defecation effect of mother and child and the excretion effect of fat and sugar. Looking for value.
그 중 모자반은 여러해살이이며, 국내외 연안에서 해중림을 이루며 분포하는 대표적인 갈조류이다. 지충이, 괭생이 모자반, 꽈배기 모자반, 큰잎 모자반, 짝잎 모자반, 쌍발이모자반 등 약 20종이 채집되며, 일본이나 동남아시아 일대에는 50여종이 생육하고 있다. 모자반 속의 많은 종류가 식용되기도 하며, 알긴산 등 해조 공업의 원료로 이용되거나 비교로 사용되고 있다. 모자반종을 이용한 항비만 소재 개발에 관하여 연구가 진행되고는 있으나, 그 기전에 대한 연구는 미미한 실정이다.Among them, the mother-in-law is a perennial, and is a representative brown algae distributed in marine forests in domestic and overseas coasts. About 20 species are collected, such as half of the worms, half of hoesaegi, half of pretzel, half of large leaves, half of pair of leaves, and half of twin hairs, and about 50 species are growing in Japan and Southeast Asia. Many kinds of the mother and child are also edible, and are used as raw materials for the seaweed industry such as alginic acid or used for comparison. Research on the development of anti-obesity materials using single-mother and child species is ongoing, but research on the mechanism is insignificant.
본 발명의 목적은 괭생이 모자반(Sargassum horneri) 추출물을 유효성분으로 포함하는 항비만용 조성물을 제공하는 것이다.An object of the present invention is to provide a composition for anti-obesity comprising an extract of Sargassum horneri as an active ingredient.
본 발명의 다른 목적은 비만 예방 또는 완화 효과가 우수한 항비만용 조성물을 제공하는 것이다.Another object of the present invention is to provide a composition for anti-obesity excellent in preventing or alleviating obesity.
본 발명의 다른 목적은 괭생이 모자반(Sargassum horneri) 추출물을 유효성분으로 포함하여, 비만 예방 및 완화 효과가 우수하고, 기호성이 높은 항비만용 식품 조성물을 제공하는 것이다. Another object of the present invention is to provide a food composition for anti-obesity having excellent anti-obesity prevention and alleviation effect and high palatability, including the extract of Sargassum horneri as an active ingredient.
본 발명의 다른 목적은 괭생이 모자반(Sargassum horneri) 추출물을 유효성분으로 포함하여, 비만 예방 및 완화 효과가 우수하고 천연물 유래 물질로 부작용이 없는 항비만용 약학 조성물을 제공하는 것이다.Another object of the present invention is to provide a pharmaceutical composition for anti-obesity, which contains an extract of Sargassum horneri as an active ingredient, has excellent anti-obesity prevention and alleviation effects, and is a natural substance-derived material without side effects.
상기 목적을 달성하기 위하여, 본 발명의 일 실시예에 따른 항비만용 조성물은 괭생이 모자반(Sargassum horneri) 추출물 및 그의 분획물을 유효성분으로 포함하며, 지방전구세포 형성 및 트리글리세리드(triglyceride)의 생성을 감소하여 비만 예방 및 완화 효과가 우수한 조성물을 제공한다.In order to achieve the above object, the composition for anti-obesity according to an embodiment of the present invention comprises a Sargassum horneri extract and a fraction thereof as an active ingredient, and the formation of adipocytes and the production of triglycerides. It provides a composition excellent in preventing and alleviating obesity by reducing.
상기 괭생이 모자반(Sargassum horneri) 추출물은 물, C₁ 내지 C5의 저급 알코올 및 이들의 혼합물로 이루어진 군으로부터 선택된 추출 용매를 이용하여 추출된다.The Sargassum horneri extract is extracted using an extraction solvent selected from the group consisting of water, C₁ to C 5 lower alcohols, and mixtures thereof.
상기 괭생이 모자반(Sargassum horneri) 추출물 및 그의 분획물을 포함하는 항비만용 조성물은 비만 전사 인자(adipogenic transcription factor)의 발현을 억제하는 조성물을 제공한다.The composition for anti-obesity comprising the extract of Sargassum horneri and a fraction thereof provides a composition for inhibiting the expression of an obesity transcription factor (adipogenic transcription factor).
본 발명의 또 다른 일 실시예에 따른 식품 조성물은 상기 항비만용 조성물을 제공한다.The food composition according to another embodiment of the present invention provides the composition for anti-obesity.
본 발명의 또 다른 일 실시예에 따른 약학 조성물은 상기 항비만용 조성물을 제공한다.The pharmaceutical composition according to another embodiment of the present invention provides the composition for anti-obesity.
상기 항비만용 약학 조성물은 약학적으로 허용되는 담체, 부형제 및 희석제로 이루어진 군으로부터 선택되는 것을 추가로 포함할 수 있다.The pharmaceutical composition for anti-obesity may further include one selected from the group consisting of a pharmaceutically acceptable carrier, excipient, and diluent.
이하, 본 발명을 더욱 상세하게 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명에서 "천연 추출물"은 천연물로부터 분리된 활성 성분을 의미한다.In the present invention, "natural extract" means an active ingredient isolated from natural products.
본 명세서에서 "예방"은 질환 또는 질병을 보유하고 있다고 진단된 적은 없으나, 이러한 질환 또는 질병에 걸리기 쉬운 경향이 있는 동물에서 질환 또는 질병의 발생을 억제하는 것을 의미한다. In the present specification, "prevention" refers to suppressing the occurrence of a disease or disease in an animal that has not been diagnosed as having a disease or disease, but is prone to such a disease or disease.
본 명세서에서 "치료"는 (a) 질환 또는 질병의 발전의 억제; (b) 질환 또는 질병의 경감; 및 (c) 질환 또는 질환의 제거를 의미한다.As used herein, "treatment" refers to (a) inhibition of the development of a disease or disease; (b) alleviation of the disease or disease; And (c) means the elimination of a disease or disorder.
본 발명의 일 실시예에 따른 항비만용 조성물은 괭생이 모자반(Sargassum horneri) 추출물 및 그의 분획물을 포함하며, 지방전구세포 형성 및 트리글리세리드(triglyceride)의 생성을 감소시켜 비만 예방 및 완화용 조성물을 제공한다. The composition for anti-obesity according to an embodiment of the present invention includes a Sargassum horneri extract and a fraction thereof, and provides a composition for preventing and alleviating obesity by reducing the formation of adipocytes and the production of triglycerides. do.
상기 괭생이 모자반(Sargassum horneri)은 생물학적으로 식물계 갈조식물군 갈조강 모자반목 모자반과로 분류되고, 북태평양 서안에 주로 분포하고 있으며, 조간대 하부에서 자란다. 국내 연안에서는 간조시에 몸의 일부분이 수면에 부표하는 것이 쉽게 관찰되며, 가장 흔한 해중림 구성 종이나, 어린 개체는 식용하고, 봄철에 암반에서 탈락되어 뜬말의 형태로 연안에 떠다닌다.The Sargassum horneri is biologically classified as a plant-based brown algae group, and is mainly distributed in the western North Pacific Ocean, and grows in the lower intertidal zone. It is easily observed that part of the body buoys on the water surface at low tide in domestic coasts, and the most common species of marine forests, but young individuals are edible, and they are removed from the bedrock in spring and float on the coast in the form of floating horses.
식물체는 황갈색이며 단추 모양의 뿌리에서 나온 줄기는 외가닥으로 길어지거나 가끔 두 갈래로 갈라지며 윗 부분에서 가지를 낸다. 현재 아토피 억제 효과, 항염증 효과, 중금속 흡착 효과에 대해 보고가 되어 있으며, 스크리닝 실험을 통헤 항산화, 지방세포 생성 억제 효과, 암세포 증식 억제 효과, 항 혈액 응고 효과 등이 보고되어 있다.The plant is yellowish brown, and the stem from the button-shaped root lengthens as a single strand or sometimes splits into two branches, and branches are made from the upper part. Currently, atopic inhibitory effect, anti-inflammatory effect, and heavy metal adsorption effect have been reported. Through screening experiments, antioxidant, adipocyte production inhibitory effect, cancer cell proliferation inhibitory effect, and anti-blood clotting effect have been reported.
또한, 알긴산 함량이 25.2%에 달하는 것으로 보고되어있고, 건조중량의 32% 이상이 식이 섬유이며, 이중 50% 이상이 수용성 식이섬유로 보고되어 있다. 이와 같이 수용성 식이섬유 함량이 높아 괭생이 모자반(Sargassum horneri)은 배변효과와 지방 및 당의 배설효과가 있는 것으로, 체중조절효과를 나타낸다.In addition, it is reported that the alginic acid content reaches 25.2%, and more than 32% of the dry weight is dietary fiber, of which 50% or more is reported as water-soluble dietary fiber. As such, because of the high content of water-soluble dietary fiber, Sargassum horneri has a bowel effect and excretion of fat and sugar, and exhibits a weight control effect.
상기 괭생이 모자반(Sargassum horneri) 추출물은 물, C₁ 내지 C5의 저급 알코올 및 이들의 혼합물로 이루어진 군으로부터 선택된 추출 용매를 이용하여 추출된다.The Sargassum horneri extract is extracted using an extraction solvent selected from the group consisting of water, C₁ to C 5 lower alcohols, and mixtures thereof.
상기 괭생이 모자반 추출물(Sargassum horneri)은 건조한 괭생이 모자반을 분쇄한 분쇄물을 에탄올, 메탄올 등과 같은 C₁ 내지 C5의 저급 알코올을 추출 용매로 추출할 수 있으며, 보다 상세하게는 추출 용매로 에탄올을 이용할 수 있다. 이때 추출 온도는 10℃ 내지 100℃, 바람직하게는 실온에서 추출한 추출물 일 수 있다.The Sargassum horneri can extract the pulverized product obtained by pulverizing the dried hoe-saeng-i hat-ban with an extraction solvent of C₁ to C 5 lower alcohol such as ethanol and methanol, and more specifically, ethanol as an extraction solvent. Can be used. At this time, the extraction temperature may be 10 ℃ to 100 ℃, preferably the extract extracted at room temperature.
상기 추출 용매는 시료의 중량 기준으로 2 내지 50배를 사용할 수 있으며, 바람직하게는 2내지 20배이다. 추출을 위해 시료는 추출 용매에서 침출을 위해 1내지 72시간 동안 방지될 수 있으며, 상세하게는 1내지 24시간 동안 방치될 수 있다.The extraction solvent may be used 2 to 50 times the weight of the sample, preferably 2 to 20 times. For extraction, the sample may be prevented for 1 to 72 hours for leaching in the extraction solvent, and in detail, may be left for 1 to 24 hours.
여과된 추출물을 진공 회전 농축기로 감압 농축하여 수득한 결과물일 수 있으나, 본 발명의 항비만 효과를 나타낼 수 있는 괭생이 모자반(Sargassum horneri) 추출물인 한, 이에 제한되지 않고, 추출액, 추출액의 희석액 또는 농축액, 추출액을 건조하여 얻어지는 건조물, 또는 이의 조정제물 또는 정제물을 모두 포함한다.The filtered extract may be a result obtained by concentrating under reduced pressure with a vacuum rotary concentrator, but as long as it is an extract of Sargassum horneri that can exhibit the anti-obesity effect of the present invention, it is not limited thereto, and the extract, a diluent of the extract, or It includes all of a concentrated solution, a dried product obtained by drying the extract, or a crude product or purified product thereof.
또한, 괭생이 모자반(Sargassum horneri) 추출물을 이용하는 경우, 해조류 특유의 이취로 인해 기능성 식품 조성물로 이용하고자 하는 경우에, 기호도가 떨어지는 문제가 있다.In addition, in the case of using the extract of Sargassum horneri, there is a problem in that the preference is deteriorated in the case of using it as a functional food composition due to off-flavor peculiar to seaweed.
이러한 문제를 방지하기 위하여, 발효 괭생이 모자반(Sargassum horneri) 추출물을 이용하는 경우 해조류 특유의 이취를 감소시켜 상대적으로 기호도를 높일 수 있다. 또한, 발효 괭생이 모자반 추출물을 이용하는 경우, 추출물 자체를 이용하는 경우에 비해, 사용량을 증가하여 섭취가 가능하다.In order to prevent this problem, when using the fermented hoesaengi Sargassum horneri extract, it is possible to relatively increase the preference by reducing the off-flavor peculiar to seaweed. In addition, when using the fermented hoesaengi mother and child extract, compared to the case of using the extract itself, it is possible to increase the amount of consumption.
상기 발효에 사용하는 미생물로는 락토바실러스 살리바리우스(Lactobacillus salivarius), 락토바실러스 아시도필루스(Lactobacillus acidophilus), 락토바실러스 브레비스(Lactobacillus brevis), 락토바실러스 람노수스(Lactobacillus rhamnosus), 락토바실러스 플랜타룸(Lactobacillus plantarum), 락토바실러스 헬베티쿠스(Lactobacillus helveticus), 락토바실러스 퍼멘툼(Lactobacillus fermentum), 락토바실러스 파라카세이(Lactobacillus paracasei), 락토바실러스 카세이(Lactobacillus casei), 락토바실러스 델브루에키(Lactobacillus delbrueckii), 락토바실러스 레우테리(Lactobacillus reuteri), 락토바실러스 부츠네리(Lactobacillus buchneri), 락토바실러스 가세리(Lactobacillus gasseri), 락토바실러스 존스니(Lactobacillus johonsonii), 락토바실러스 케피르(Lactobacillus kefir) 등과 같은 유산 바실리, 락토코코스 락티스(Lactococcus lactis), 락토코코스 플랜타룸(Lactococcus plantarum), 락토코코스 라피노락티스(Lactococcus raffinolactis), 엔테로코코스파에칼리스(Enterococcus faecalis), 엔테로코코스 파에시늄(Enterococcus faecium), 스트렙토코코스 터모필리우스(Streptococcus thermophilus), 류코노스톡락티스(Leuconostoc lactis), 류코노스톡 메센테로이드(Leuconostoc mesenteroides) 등과 같은 유산 콕사이 및 비피도박테리움 애닐멀스(Bifidobacterium animals), 비피도 박테리움 비피듐(Bifidobacterium bifidum),비피도박테리움 브레브(Bifidobacterium breve), 비피도박테리움 인판티스(Bifidobacterium infantis), 비피도바테리움 롱굼(Bifidobacterium longum), 비피도박테리움 수도롱굼(Bifidobacterium pseudolongum), 비피도박테리움 터모필룸(Bifidobacterium themophilum), 비피도박테리움 아돌센티스(Bifidobacterium adolescentis) 등과 같은 비피도박테리아를 포함할 수 있으며, 더욱 바람직하게는 락토바실러스 카제이(Lactobacillus casei), 락토바실러스 람노수스(Lactobacillus rhamnosus), 비피도 박테리윰 비피듐(Bifidobacterium bifidum) 비피더스균, 비피도 박테리움 브레브(Bifidobacterium breve) 비피더스균, 및 락토바실러스 아시도 필루스(Lactobacillus acidophilus)로 이루어진 군에서 선택되는 하나 이상인 것일 수 있다.Microorganisms used for the fermentation include Lactobacillus salivarius, Lactobacillus acidophilus, Lactobacillus brevis, Lactobacillus rhamnosus, Lactobacillus rhamnosus Lactobacillus plantarum), Lactobacillus helveticus, Lactobacillus fermentum, Lactobacillus paracasei, Lactobacillus casei, Lactobacillus casei, Lactobacillus casei, Lactobacillus deleckii, Lactobacillus deleckii Lactobacillus reuteri, Lactobacillus buchneri, Lactobacillus gasseri, Lactobacillus johonsonii, Lactobacillus kefir, Lactobacillus kefir, Lactobacillus kefir, etc. Cocos lactis (Lactococcus lactis), Lactococcus plantarum (Lactococcus plantarum), Lactococcus raffinolactis, Enterococcus faecalis (Enterococcus faecalis), Enterococcus faecium (Enterococcus faecium), Streptococcus faecium Lactobacillus and Bifidobacterium animals such as Streptococcus thermophilus, Leuconostoc lactis, and Leukonostoc mesenteroides, Bifidobacterium animals, Bifidobacterium bipidium (Bifidobacterium bifidum), Bifidobacterium breve (Bifidobact) erium breve), Bifidobacterium infantis, Bifidobacterium longum, Bifidobacterium pseudolongum, Bifidobacterium themophilum, Bifidobacterium It may include Bifidobacteria such as Bifidobacterium adolescentis, and more preferably Lactobacillus casei, Lactobacillus rhamnosus, Bifidobacterium Bifidobacterium bifidum) Bifidobacterium, Bifidobacterium breve Bifidobacterium, and Lactobacillus acidophilus (Lactobacillus acidophilus) It may be one or more selected from the group consisting of.
본 발명의 항비만용 조성물은 괭생이 모자반(Sargassum horneri) 추출물 및 그의 분획물을 포함하며, 비만 전사 인자(adipogenic transcription factor)의 발현을 억제하는 것이다.The composition for anti-obesity of the present invention comprises an extract of Sargassum horneri and a fraction thereof, and inhibits the expression of an obesity transcription factor.
구체적으로, 괭생이 모자반(Sargassum horneri)추출물은 비만 전사 인자(adipogenic transcription factor) 발현의 억제를 통해 지방세포 분화를 억제하였으며, 지방전구세포 형성과 트리글리세리드(triglyceride)의 생성을 감소하여 항비만 효과를 나타낼 수 있다.Specifically, Sargassum horneri extract inhibited adipocyte differentiation by inhibiting the expression of adipogenic transcription factor, and reduced the formation of adipocytes and the production of triglycerides, resulting in an anti-obesity effect. Can be indicated.
보다 구체적으로, 비만은 지방전구세포의 분화 및 지질합성(adipogenesis) 과정에서 과잉의 에너지 공급으로 인한 지방세포 내 중성지방 (triglyceride)의 과도한 축적으로 발생하는 것이다.More specifically, obesity is caused by excessive accumulation of triglycerides in adipocytes due to excessive energy supply during the differentiation and adipogenesis of adipocytes.
이러한 비만의 발생 원인에 비추어, 본 발명은 괭생이 모자반 추출물을 이용하여, SREBP-1c과 같은 비만 전사 인자의 발현을 억제함에 따라, 지방 세포 분화를 억제할 수 있다. 즉, 지방 세포에서 분비되는 아디포카인(adipokine)의 조절과 지방 세포 내의 신호전달경로를 억제하여, 지방 세포 분화를 억제할 수 있다.In view of the cause of obesity, the present invention suppresses the expression of obesity transcription factors such as SREBP-1c by using the extract of hoe-saeng-i, and thus adipocyte differentiation can be suppressed. In other words, it is possible to inhibit adipocyte differentiation by regulating adipokine secreted from adipocytes and inhibiting signaling pathways within adipocytes.
상기 트리글리세리드(triglyceride)는 지질의 한 종류로 글리세린 한 분자에 지방산 3분자가 에스터 결합을 하는 구조로, 중성지방으로도 불린다. 중성 지방은 앞서 설명한 바와 같이, 체내에 남는 에너지가 중성지방의 형태로 축적되는 것으로, 콜레스테롤과 함께 관상동맥질환의 원인이 된다. The triglyceride is a type of lipid, and has a structure in which three molecules of fatty acids are ester bonded to one molecule of glycerin, and is also called triglyceride. As described above, triglycerides are the energy remaining in the body is accumulated in the form of triglycerides and, together with cholesterol, cause coronary artery disease.
이에, 본 발명은 괭생이 모자반 추출물을 이용하여, 지방전구세포 형성 및 트리글리세리드(triglyceride)의 합성을 저해시켜, 항비만 효과를 나타낼 수 있다.Accordingly, the present invention may exhibit an anti-obesity effect by inhibiting the formation of adipocytes and the synthesis of triglycerides by using the extract of hoe-saengi mother and child.
상기 괭생이 모자반 추출물만을 이용하는 경우와 비교하여, 천연 추출물을 추가로 혼합한 천연 복합 추출물로 구성하는 경우, 항비만 효과를 더욱 상승시킬 수 있다. Compared with the case of using only the hoesaengi maternal extract, when the natural extract is additionally mixed with a natural complex extract, the anti-obesity effect can be further increased.
이때, 바람직하게 상기 천연 추출물은 낭아초 추출물, 일엽초 추출물, 곤달비 추출물 및 이들의 혼합물로 이루어진 군으로부터 선택된 천연 추출물을 포함할 수 있다. In this case, preferably, the natural extract may include a natural extract selected from the group consisting of cystic vinegar extract, monophylla extract, gondalbi extract, and mixtures thereof.
일엽초(Lepisorus thunbergianus (Kaulf.) Ching)는 상록다년초로서 근경이나 포자로 번식한다. 제주도와 남부지방에 분포하며 습기가 많은 바위 겉이나 노목의 줄기 겉에 붙어서 자란다. 옆으로 벋는 근경은 지름 2 내지 3mm정도이고, 겉에 좁은 피침형의 인편이 있다. 잎은 마디 사이가 짧은 근경에서 나오므로 모여 나는 것 같으며, 선형으로 길이 10 내지 20츠 정도이고, 끝이 뾰족하다. 포자낭군은 둥글며 뒷면 윗부분 주맥 양쪽에 1줄로 달리고 누른빛이 돈다. 포막은 없다. 근경이 굵고 지름이 2 내지 3mm 정도이며 잎은 길이 10 내지 30츠, 너비 5 내지 15mm 정도인 것이 '애기 일엽초'와 다르다. 관상용, 분재용으로 쓰이기도 하며, 약용으로 쓰인다.One leaf plant (Lepisorus thunbergianus (Kaulf.) Ching) is an evergreen perennial plant that reproduces with rhizomes or spores. It is distributed in Jeju Island and southern regions and grows attached to the surface of moist rocks or trunks of old trees. The rhizome is about 2 to 3mm in diameter and has narrow lanceolate scales on the outside. The leaves come out from the short root diameter between the nodes, so they seem to come together, linearly, about 10 to 20 ts long, and the tip is sharp. The sporangia group is round and runs in one row on both sides of the main vein of the upper part of the back and turns yellow. There is no curtain. The rhizome is thick, the diameter is about 2 to 3 mm, and the leaves are 10 to 30 ts in length and 5 to 15 mm in width, which is different from the'Aggi single leaf herb'. It is also used for ornamental, bonsai, and medicinal purposes.
낭아초는 낙엽 활엽반관목으로, 가지를 많이 쳐서 옆으로 자라며, 작은 가지에는 복모가 있고 가늘다. 높이는 2m 정도이다. 잎은 작은 잎이 5 내지 11개이고, 타원상 도란형, 타원형 또는 긴 타원형이며, 잎자루는 1 내지 3cm인, 홀수깃꼴겹잎이다. 가장 자리는 밋밋하고 잎끝이 둔하거나 오목하고, 잎밑은 둥글다. 뿌리 부위는 약용으로 쓰인다.Cygnus is a deciduous broad-leaved semi-shrub, and grows sideways by striking a lot of branches, and the small branches have coat hairs and are thin. The height is about 2m. Leaves are 5 to 11 small leaves, oval obovate, oval or long oval, petiole is 1 to 3 cm, odd pinnate compound leaves. The edge is flat and the tip of the leaf is dull or concave, and the bottom of the leaf is round. The root area is used for medicinal purposes.
곤달비(Ligularia stenocephala)는 깊은 산의 습지에서 자란다. 높이 60∼100cm이다. 풀 전체에 털이 없고 뿌리줄기가 굵다. 뿌리에 달린 잎은 꽃이 필 때까지 남아 있는데 길이 24cm, 나비 20cm 정도이다. 잎 뒷면 맥을 따라 털이 나며 가장자리에 뾰족한 톱니가 있다. 잎자루는 길이 40cm 정도로 날개가 없고 밑쪽이 넓다. 줄기에 달린 잎은 3개로 아래쪽 것은 뿌리에 달린 잎과 거의 같으나, 위쪽으로 갈수록 잎자루가 짧아져서 잎집이 되고 잎도 작아진다. 꽃은 노란색으로 8∼9월에 줄기 끝에 총상꽃차례로 달린다. 밑에서 위로 피며 지름 3cm 정도이다. 포는 바소꼴이며 길이 2∼3mm이고 꽃자루는 길이 1∼3.5cm이다. 총포는 좁은 통 모양이고 포조각은 5개이다. 화관은 길이 20∼25mm, 나비 3∼4mm이다. 관모는 화관보다 짧으며 연한 갈색이다. 열매는 수과로 10월에 익으며 거꾸로 선 바소꼴이다. 빛깔은 갈색이 도는 흰색이며 길이 6∼7mm이다.The gondalbi (Ligularia stenocephala) grows in deep mountain wetlands. It is 60-100cm in height. There is no hair on the whole grass, and the rootstock is thick. The leaves on the root remain until the flowers bloom, and the length is 24cm and the butterfly is about 20cm. There are hairs along the veins on the back of the leaf, and there are sharp saw teeth on the edge. The petiole is 40cm long, has no wings, and the bottom is wide. There are 3 leaves on the stem, and the lower one is almost the same as the leaf on the root, but the petiole becomes shorter as it goes upward, making the leaf sheath and the leaf smaller. The flowers are yellow and hang in a racemic order at the end of the stem from August to September. It blooms from bottom to top and is about 3cm in diameter. Bracts are lanceolate, 2~3mm long, and
상기 낭아초 추출물, 일엽초 추출물 및 곤달비 추출물은 괭생이 모자반 추출물과 동일한 추출 방법을 이용하여 추출된 추출물이다. The cystocarps extract, monophyllum extract, and gondalbi extract are extracts extracted using the same extraction method as that of the hoesaengi maternal extract.
상기 괭생이 모자반 추출물에, 낭아초 추출물, 일엽초 추출물, 곤달비 추출물 및 이들의 혼합물로 이루어진 군으로부터 선택된 천연 추출물을 포함하는 경우, 괭생이 모자반 추출물을 단독으로 사용하는 경우와 비교하여, 각 구성 성분간의 혼합 사용에 따른 활성으로 인해, 항비만 효과가 상승하게 된다. In the case of containing a natural extract selected from the group consisting of cystweed extract, monophyllum extract, gondalbi extract, and mixtures thereof in the hoesaengi hatban extract, compared to the case of using the hoexaenggi hatban extract alone, mixing of each component Due to the activity according to the use, the anti-obesity effect is increased.
바람직하게 본 발명의 일 실시예에 따른 항비만용 조성물은 괭생이 모자반 추출물, 낭아초 추출물, 일엽초 추출물 및 곤달비 추출물을 포함할 수 있다. Preferably, the composition for anti-obesity according to an embodiment of the present invention may include a hoesaengi mother and child extract, a cystocarp extract, a monoleaf extract and a gondalbi extract.
보다 바람직하게 상기 항비만용 조성물은 괭생이 모자반 추출물 100 중량부에 대하여, 낭아초 추출물 40 내지 60 중량부, 일엽초 추출물 40 내지 60 중량부 및 곤달비 추출물 40 내지 60 중량부로 포함할 수 있다. 상기 수치 범위 내에서의 사용에 의하는 경우, 각 구성 성분 간의 혼합 사용에 따른 복합 작용으로 인해, 항비만 효과가 상승하게 된다. More preferably, the composition for anti-obesity may include 40 to 60 parts by weight of cystweed extract, 40 to 60 parts by weight of Japanese herbaceous plant extract, and 40 to 60 parts by weight of gondalbi extract based on 100 parts by weight of hoesaengi mother and child extract. In the case of use within the above numerical range, the anti-obesity effect increases due to the complex action resulting from the mixed use of each component.
본 발명의 또 다른 일 실시예에 따른 식품 조성물은 상기 항비만용 조성물을 포함한다.The food composition according to another embodiment of the present invention includes the anti-obesity composition.
본 발명에서 말하는 항비만용 조성물은 좁은 의미로 비만 예방 및 완화용 식품 조성물을 의미한다.The anti-obesity composition referred to in the present invention means a food composition for preventing and alleviating obesity in a narrow sense.
상기 본 발명의 항비만용 조성물을 기능성 식품 조성물로 제공하는 경우, 괭생이 모자반 추출물, 낭아초 추출물, 일엽초 추출물 및 곤달비 추출물은 천연 추출물로 추출물로 제조 시, 고유의 향과 맛이 그대로 전달되어, 기호성이 낮은 문제가 있다. In the case of providing the composition for anti-obesity of the present invention as a functional food composition, the hoesaengi chinensis extract, cystweed extract, monophyllum extract and gondalbi extract are natural extracts, and when prepared as extracts, their unique aroma and taste are delivered as they are, and palatability I have this low problem.
이러한 문제를 방지하기 위해, 화학 조미료를 이용하는 방법도 고려될 수 있으나, 화학 조미료를 이용하는 것은, 본 발명에서 부작용이 없는 천연 조성물로 기능성 식품 조성물을 제공하는 취지에 부합하지 않는 점을 고려할 때, 바람직하지 않은 문제가 있다. In order to prevent this problem, a method of using a chemical seasoning may also be considered, but the use of a chemical seasoning is preferable when considering the point that does not conform to the purpose of providing a functional food composition with a natural composition without side effects in the present invention. There is a problem that has not been done.
이러한 문제를 방지하기 위해, 보다 바람직하게 본 발명에서는 기호성을 향상시키기 위해, 수호초(Pachysandra terminalis) 추출물 및 나한과((Siraitia grosvenorii) 추출물을 추가로 포함할 수 있다.In order to prevent such a problem, more preferably, in the present invention, in order to improve palatability, it may further include an extract of Pachysandra terminalis and an extract of Siraitia grosvenorii.
상기 수호초(Pachysandra terminalis)는 나무 그늘에서 자라며 원줄기가 옆으로 벋으면서 끝이 곧추서고 녹색이며 처음에는 잔 털이 있으나 점차 없어진다. 높이 30cm 내외로 자란다. 잎은 어긋나지만 윗부분에 모여 달리고 달걀을 거꾸로 세운 듯한 모양이며 윗부분에 톱니가 있다. 잎 표면 맥 위에 잔털이 있고 밑부분이 좁아져 잎자루가 된다. 또한 꽃은 4 또는 5월에 피고 흰색이며 수상꽃차례에 달린다. 암꽃은 꽃이삭 밑부분에 약간 달리고 수꽃은 윗부분에 많이 달린다. 꽃받침은 4개로 갈라지고 꽃잎은 없다. 수술은 3 내지 5개이고 암술대는 2개로 갈라져서 젖혀진다. 열매는 핵과로서 달걀 모양이고 겉에 털이 없다. 한국, 일본, 사할린섬, 중국에 분포한다.The pachysandra terminalis grows in the shade of a tree, and the end is upright and green with the main stem being sideways, and at first, fine hairs, but gradually disappear. It grows around 30cm in height. The leaves are alternate, but they run together on the upper part, and the egg looks like it is upside down, and there are serrations on the upper part. There are fine hairs on the veins on the leaf surface, and the lower part becomes narrow to become a petiole. Also, flowers bloom in April or May, are white, and hang on water inflorescences. Female flowers hang slightly at the bottom of the flower head, and male flowers hang at the top. The calyx is divided into 4 and there are no petals. The number of stamens is 3 to 5, and the style is split into two and turned over. The fruit is a drupe, egg-shaped and hairless on the outside. It is distributed in Korea, Japan, Sakhalin Island, and China.
나한과((Siraitia grosvenorii)는 조롱박과의 초본 다년생 식물이며 중국 및 태국 등지에 자생한다. 나한과의 열매와 잎은 한방에서 약 재로 사용하는데, 주로 고랭지에서 자생하며 안개가 많고 서늘한 기후와 햇볕을 좋아하고 배수가 잘되며 부식질 이 많은 토양에서 서식하므로 재배조건이 까다로워 인위적인 재배가 어려운 식물로 예로부터 귀한 약재로 사용되어 왔다.Siraitia grosvenorii (Siraitia grosvenorii) is a herbaceous perennial plant of the gourd family and grows wildly in China and Thailand. The fruits and leaves of the Siraitia grosvenorii are used as medicinal materials in herbal medicine, mainly growing in highlands, with a lot of fog and a cool climate It is a plant that is difficult to cultivate artificially due to difficult cultivation conditions because it is fond, well-drained and lives in a lot of humus, and has been used as a valuable medicinal material from ancient times.
상기 수호초 추출물 및 나한과 추출물을 추가로 포함함에 따라, 괭생이 모자반 추출물, 낭아초 추출물, 일엽초 추출물 및 곤달비 추출물만을 사용하는 경우에 비해, 항비만 효과는 높이며, 기호성이 우수한 기능성 식품 조성물로의 제공을 가능하게 한다. As compared to the case of using only the Suho-cho extract and Nahan fruit extract, as compared to the case of using only the hoesaengi mosquito extract, cystocarp extract, monophylla extract and gondalbi extract, the anti-obesity effect is increased and provided as a functional food composition having excellent palatability Makes it possible.
보다 바람직하게 상기 항비만용 조성물은 괭생이 모자반 추출물 100 중량부에 대하여, 낭아초 추출물 40 내지 60 중량부, 일엽초 추출물 40 내지 60 중량부, 곤달비 추출물 40 내지 60 중량부, 수호초 추출물 20 내지 30 중량부 및 나한과 추출물 30 내지 50 중량부로 포함할 수 있다. 상기 수치 범위 내에서의 사용에 의하는 경우, 각 구성 성분 간의 혼합 사용에 따른 복합 작용으로 인해, 기호성이 우수한 식품 조성물로의 제공이 가능하며, 항비만 효과가 상승하게 된다. More preferably, the composition for anti-obesity is based on 100 parts by weight of hoesaengi mother and child extract, 40 to 60 parts by weight of cystocarp extract, 40 to 60 parts by weight of Japanese herb extract, 40 to 60 parts by weight of gondalbi extract, 20 to 30 parts by weight of Suhocho extract It may be included in an amount of 30 to 50 parts by weight of parts and nahan fruit extract. In the case of use within the above numerical range, due to the complex action caused by the mixed use of each component, it is possible to provide a food composition having excellent palatability, and the anti-obesity effect is increased.
구체적인 예로, 상기 식품 조성물을 이용하여 비만 예방 및 완화효과를 증강시킬 수 있는 가공식품을 제조할 수 있다. 이런 가공식품에는 예를 들어, 과자, 음료, 주류, 발효식품, 통조림, 우유가공식품, 육류가공식품, 국수 등을 포함한다. 과자는 비스킷, 파이, 케익, 빵, 캔디, 젤리, 껌, 시리얼등을 포함한다. 음료는 음용수, 탄산음료, 기능성 이온음료, 기능성이온음료, 주스(예를들어, 사과, 배, 포도, 알로에, 감귤, 복숭아, 당근, 토마토 쥬스 등), 식혜 등을 포함한다. 주류는 청주, 위스키, 소주, 맥주, 양주, 과실주 등을 포함한다. 발효식품은 간장, 된장, 고추장 등을 포함한다. 통조림은 수산물 통조림(예들 들어, 참치, 고등어, 꽁치, 소라 통조림 등), 축산물 통조림(쇠고기, 돼지고기, 닭고기, 칠면조 통조림 등), 농산물 통조림(옥수수, 복숭아, 파일애플 통조림 등)을 포함한다. 우유가공식품은 치즈, 버터, 요구르트 등을 포함한다. 육류가공식품은 돈까스, 비프까스, 치킨까스, 소세지. 탕수육, 너겟류, 너비아니 등을 포함한다. 밀봉포장생면 등의 국수를 포함한다. 이 외에도 상기 조성물은 레토르트식품, 스프류 등에 사용될 수 있다.As a specific example, processed foods capable of enhancing obesity prevention and alleviation effects may be prepared by using the food composition. These processed foods include, for example, confectionery, beverages, alcoholic beverages, fermented foods, canned foods, processed milk foods, processed meat foods, noodles, and the like. Cookies include biscuits, pies, cakes, bread, candy, jelly, gum, and cereal. Beverages include drinking water, carbonated beverages, functional ionic beverages, functional ionic beverages, juices (for example, apples, pears, grapes, aloe, tangerines, peaches, carrots, tomato juice, etc.), and sikhye. Alcoholic beverages include sake, whiskey, shochu, beer, Western liquor, and fruit liquor. Fermented foods include soy sauce, soybean paste, and red pepper paste. Canned food includes canned seafood (e.g., canned tuna, mackerel, saury, conch, etc.), canned livestock (beef, pork, chicken, canned turkey, etc.), canned agricultural products (canned corn, peaches, pile apples, etc.). Milk processed foods include cheese, butter, and yogurt. Meat processed foods are pork cutlet, beef cutlet, chicken cutlet, and sausage. Includes sweet and sour pork, nuggets, and width. Includes noodles such as sealed and packaged fresh noodles. In addition, the composition may be used for retort foods, soups, and the like.
본 발명의 또 다른 일 실시예에 따른 약학 조성물은 상기 항비만용 조성물을 포함한다.The pharmaceutical composition according to another embodiment of the present invention includes the anti-obesity composition.
상기 항비만용 약학 조성물은 약학적으로 허용되는 담체, 부형제 및 희석제로 이루어진 군으로부터 선택되는 것을 추가로 포함할 수 있다. 구체적으로, 상기 약학 조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 본 발명에서, 상기 약학적 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화 할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 추출물과 이의 분획물들에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘 카보네이트(calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스티레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는 데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.The pharmaceutical composition for anti-obesity may further include one selected from the group consisting of a pharmaceutically acceptable carrier, excipient, and diluent. Specifically, the pharmaceutical compositions are formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, and other oral formulations, external preparations, suppositories, and sterile injectable solutions, respectively, according to conventional methods. I can. In the present invention, the carrier, excipient, and diluent that may be included in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate. , Calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. In the case of formulation, it is prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants that are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and these solid preparations include at least one excipient, such as starch, calcium carbonate, in the extract and its fractions, It is prepared by mixing sucrose or lactose, gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral use include water and liquid paraffin, which are simple diluents commonly used for suspensions, liquid solutions, emulsions, and syrups, and various excipients such as wetting agents, sweetening agents, fragrances, and preservatives. have. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate may be used. As a base for suppositories, witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin, and the like may be used.
상기 본 발명의 약학 조성물은 약제학적으로 유효한 양으로 투여될 수 있는데, 본 발명의 용어 "약제학적으로 유효한 양"이란 의학적 치료 또는 예방에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료 또는 예방하기에 충분한 양을 의미하며, 유효 용량 수준은 질환의 중증도, 약물의 활성, 환자의 연령, 체중, 건강, 성별, 환자의 약물에 대한 민감도, 사용된 본 발명 조성물의 투여 시간, 투여 경로 및 배출 비율 치료기간, 사용된 본 발명의 조성물과 배합 또는 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. 본 발명의 약학 조성물은 단독으로로 투여하거나 공지된 면역치료제와 병용하여 투여될 수 있다. 상기 요소를 모두 고려하여 부작용 없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하다.The pharmaceutical composition of the present invention may be administered in a pharmaceutically effective amount, and the term "pharmaceutically effective amount" of the present invention is used to treat or prevent a disease at a reasonable benefit/risk ratio applicable to medical treatment or prevention. It means a sufficient amount, and the effective dose level is the severity of the disease, the activity of the drug, the patient's age, weight, health, sex, the patient's sensitivity to the drug, the time of administration of the composition of the present invention used, the route of administration and the rate of excretion. The duration, factors including drugs used in combination or co-use with the composition of the present invention used, and other factors well known in the medical field. The pharmaceutical composition of the present invention may be administered alone or may be administered in combination with a known immunotherapeutic agent. Considering all of the above factors, it is important to administer an amount capable of obtaining the maximum effect in a minimum amount without side effects.
본 발명의 항비만 조성물은 천연 재료인 괭생이 모자반(Sargassum horneri) 추출물을 이용하여, 항비만 효과를 나타냄과 동시에 비만 예방 및 완화 효과가 우수하다.The anti-obesity composition of the present invention uses an extract of Sargassum horneri, a natural material, and exhibits an anti-obesity effect and is excellent in preventing and alleviating obesity.
본 발명에 따라 상기 괭생이 모자반(Sargassum horneri) 추출물을 포함하는 항비만용 조성물을 포함하는 식품 조성물을 제조할 수 있으며, 천연물 유래 물질로 부작용이 없는 항비만용 약학 조성물을 제조가 가능하다.According to the present invention, a food composition comprising a composition for anti-obesity including the extract of Sargassum horneri can be prepared, and a pharmaceutical composition for anti-obesity without side effects can be prepared with a natural substance-derived substance.
도 1은 본 발명의 괭생이 모자반(Sargassum horneri) 에탄올 추출물이 분화된 3T3-L1 지방전구세포의 위상차 현미경 형태 변화에 미치는 영향을 나타낸 것이다.
도 2는 본 발명의 일 실시예에 따른 분화된 3T3-L1 전 지방 세포의 지방 소립 축적 억제에 대한 괭생이 모자반(Sargassum horneri) 에탄올 추출물의 효과를 나타내는 그래프이다.
도 3은 본 발명의 일 실시예에 따른 3T3-L1 지방전구세포 분화에서 웨스턴 블롯 분석(Western blot)을 나타낸 것이다.
도 4는 본 발명의 일 실시예에 따른 웨스턴 블롯 분석(Western blot)에 의한 비만 전사 인자의 단백질 발현 수준에 미치는 괭생이 모자반(Sargassum horneri) 에탄올 추출물의 영향을 나타낸 그래프이다.1 shows the effect of the ethanol extract of Sargassum horneri of the present invention on the change in the shape of the differentiated 3T3-L1 adipocytes under a phase contrast microscope.
2 is a graph showing the effect of ethanol extract of Sargassum horneri on inhibiting the accumulation of fat particles in differentiated 3T3-L1 pre-adipocytes according to an embodiment of the present invention.
Figure 3 shows a Western blot analysis (Western blot) in 3T3-L1 adipocyte differentiation according to an embodiment of the present invention.
Figure 4 is a graph showing the effect of the ethanol extract Sargassum horneri on the protein expression level of obesity transcription factor by Western blot analysis according to an embodiment of the present invention.
이하, 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있도록 본 발명의 실시예에 대하여 상세히 설명한다. 그러나 본 발명은 여러 가지 상이한 형태로 구현될 수 있으며 여기에서 설명하는 실시예에 한정되지 않는다.Hereinafter, embodiments of the present invention will be described in detail so that those skilled in the art can easily implement the present invention. However, the present invention may be implemented in various different forms and is not limited to the embodiments described herein.
[제조예 1: 천연 추출물의 제조][Production Example 1: Preparation of natural extract]
1. 괭생이 모자반 에탄올 추출물의 제조1. Preparation of Ethanol Extract of Moxa and Banana
건조 분쇄된 가루 형태의 괭생이 모자반(Sargassum horneri) 원시료 50g을 300mL의 에탄올에 넣고 60℃에서 2시간 동안 교반 자석 막대를 이용하여 고루 혼합하였다.50 g of the raw material of Sargassum horneri in the form of dry pulverized powder was added to 300 mL of ethanol and mixed evenly at 60° C. for 2 hours using a magnetic stir bar.
10,000RPM에서 10분간 원심분리 과정을 거친 후 상등 액을 취하고 300ML의 에탄올을 추가로 첨가하여 60℃에서 1시간 동안 추가로 혼합하였다. 또 다시 상등액을 취합한 후 여과 필터를 통해 부분 정제하였다. After centrifugation at 10,000 RPM for 10 minutes, the supernatant was taken, and 300ML of ethanol was added thereto, followed by further mixing at 60° C. for 1 hour. Again, the supernatant was collected and partially purified through a filtration filter.
농축기를 이용하여 45℃로 내부 온도를 설정한 오븐에 진공을 걸어 원추출물을 완전 건조시켜 제조하였다.It was prepared by completely drying the original extract by applying a vacuum to an oven with an internal temperature of 45°C using a concentrator.
2. 기타 천연 추출물의 제조2. Preparation of other natural extracts
상기 괭생이 모자반 추출물(ES)의 제조 방법과 동일한 방법을 이용하여, 낭아초 추출물(RS), 일엽초 추출물(TS), 곤달비 추출물(US), 수호초 추출물(PS) 및 나한과 추출물(QS)를 제조하였다.Using the same method as the preparation method of the hoesaengi hatban extract (ES), cysts extract (RS), monophylla extract (TS), gondalbi extract (US), suhochok extract (PS) and nahan fruit extract (QS) Was prepared.
3. 복합 추출물의 제조3. Preparation of complex extract
상기 괭생이 모자반 추출물(ES), 낭아초 추출물(RS), 일엽초 추출물(TS), 곤달비 추출물(US), 수호초 추출물(PS) 및 나한과 추출물(QS)을 하기 표 1과 같이 혼합하여 복합 추출물을 제조하였다. The composite extract by mixing the hoesaengi hatban extract (ES), cystocarps extract (RS), monophylla extract (TS), gondalbi extract (US), suhoweed extract (PS) and nahan fruit extract (QS) as shown in Table 1 below. Was prepared.
[실시예 1: 항비만 효과 검증][Example 1: Anti-obesity effect verification]
1. 지방전구세포 형성 및 트리글리세리드(triglyceride)의 생성 감소 효과 검토1. Review of the effect of reducing the formation of adipocytes and the production of triglycerides
3T3-L1 지방전구세포에서 괭생이 모자반(Sargassum horneri) 에탄올 추출물(E1)이 지방세포 분화 억제에 미치는 영향을 확인하기 위해 오일 레드(Oil Red) O 시약으로 분화 시 나타나는 지방 소립(lipid droplet)을 염색하였으며, 위상차 현미경으로 관찰하여 나타내었다. To confirm the effect of ethanol extract (E1) of Sargassum horneri on the inhibition of adipocyte differentiation in 3T3-L1 adipocytes, lipid droplets appearing during differentiation with Oil Red O reagent were used. It was stained and observed with a phase contrast microscope.
도 1은 괭생이 모자반(Sargassum horneri) 에탄올 추출물(E1)이 분화된 3T3-L1 지방전구세포의 위상차 현미경 형태 변화에 미치는 영향을 나타낸 것으로, 도 1에서 처럼 분화 유도제를 처리하지 않은 군에 비해 분화유도제 처리가 지방전구세포를 활발하게 형성하였으며, 괭생이 모자반(Sargassum horneri) 에탄올 추출물(E1)을 처리하였을 때의 지방 소립(lipid droplet)은 농도 의존적으로 감소하였다.1 shows the effect of the ethanol extract (E1) of Sargassum horneri on the change in the shape of the differentiated 3T3-L1 adipocytes under the phase contrast microscope. The inducer treatment actively formed adipocytes, and the lipid droplets when treated with ethanol extract (E1) of Sargassum horneri decreased in a concentration-dependent manner.
도 2에 따르면, 괭생이 모자반(Sargassum horneri) 에탄올 추출물(E1) 처리가 분화 유도제만 처리한 대조군에 비해 250, 500, 1,000 ㎍/ml 농도에서 13%, 16%, 23%의 트리글리세리드(triglyceride) 생성 억제 효과를 확인하였다.According to FIG. 2, treatment with ethanol extract (E1) of Sargassum horneri was 13%, 16%, and 23% triglyceride at a concentration of 250, 500, 1,000 μg/ml compared to the control group treated with only the differentiation inducing agent. The production inhibition effect was confirmed.
괭생이 모자반(Sargassum horneri) 에탄올 추출물(E1)은 지방을 염색시키기 위해 사용된 오일 레드 (Oil Red) O 시약과 트리글리세이드 함량(triglyceride content)을 통해 3T3-L1 지방전구세포에서 지방세포로 분화되는 과정을 억제하는데 효과가 있음을 확인 하였다.Sargassum horneri ethanol extract (E1) is differentiated from 3T3-L1 adipocytes into adipocytes through the oil red O reagent and triglyceride content used to stain fat. It was confirmed that it is effective in inhibiting the process.
2. 비만 전사 인자(adipogenic transcription factor) 발현 억제 효과 검토2. Review of the effect of inhibiting the expression of adipogenic transcription factor
괭생이 모자반(Sargassum horneri) 에탄올 추출물(E1)의 지방세포 분화억제에 대한 효과가 비만 전사 인자(adipogenic transcription factor)의 발현에 어떠한 영향을 미치는지 알아보기 위하여 웨스턴 블롯 분석(Western blot assay)을 통해 분화가 완료된 세포들을 수확(harvest)한 후, 세포 화합물(lysis buffer)을 첨가하여 4℃에서 1시간 동안 반응시켰다. Differentiation through Western blot assay to find out how the effect of ethanol extract (E1) of Sargassum horneri on the inhibition of adipocyte differentiation affects the expression of adipogenic transcription factor. After harvesting the completed cells, a cell compound (lysis buffer) was added and reacted at 4° C. for 1 hour.
14,000RPM에서 30분 원심 분리하여 상층액에 있는 단백질을 분리하였다. 바이오-라드(Bio-Rad) 단백질 정량 시약을 통해 단백질의 농도를 정량하였고, 그 값에 따라 표본(sample), 세포 화합물(lysis buffer), 바이로-라드(Bio-rad)와 2-머캅토에탄올(2-mercaptoethanol)를 첨가하였다. 동량의 표본(sample)을 겔 전기 영동 기술(sodium dodecyl sulphate (SDS)-polyacrylamide gel)을 이용하여 전기영동으로 분리하였고, PVDF 멤브레인(membrane)에 전이시켰다. The protein in the supernatant was separated by centrifugation at 14,000 RPM for 30 minutes. The concentration of the protein was quantified using a Bio-Rad protein quantification reagent, and according to the value, the sample, cell compound (lysis buffer), Bio-rad and 2-mercapto Ethanol (2-mercaptoethanol) was added. The same amount of sample was separated by electrophoresis using a gel electrophoresis technique (sodium dodecyl sulphate (SDS)-polyacrylamide gel), and transferred to a PVDF membrane.
5% 탈지유(skim milk)를 처리하여 비특이적인 단백질 반응을 막았으며, 1차 항체를 4℃에서 O/N 시킨 후 그에 맞는 2차 항체를 처리하여 상온에서 1 시간 반응시켰다. 특정 단백질의 발현 양상은 써모 싸이언티픽(Thermo scientific)을 사용하여 알파 이노테크(Alpha innotech)기기를 통해 분석하였다.Non-specific protein reaction was prevented by treatment with 5% skim milk, and the primary antibody was O/N at 4°C, and then the secondary antibody was treated and reacted at room temperature for 1 hour. The expression pattern of a specific protein was analyzed using an Alpha innotech instrument using Thermo Scientific.
도 3은 웨스턴 블롯 분석 결과로, 괭생이 모자반 에탄올 추출물(E1)을 처리한 군에서 비만 전사 인자의 발현이 감소됨을 확인하였다. 3 is a Western blot analysis result, it was confirmed that the expression of the obesity transcription factor was reduced in the group treated with the ethanol extract (E1) of hoesaengi.
이를 보다 구체적으로 확인하기 위하여, 비율(ratio)로 나타낸 도 4에 따르면, MDI를 처리하여 분화를 유도하였을 때 비만 전사 인자(adipogenic transcription factor)인 C/EBPα, C/EBPβ, PPARγ의 발현이 증가하였으나, 괭생이 모자반(Sargassum horneri) 에탄올 추출물(E1)을 250, 500, 1,000 ㎍/ml 농도로 처리하였을 때는 농도 의존적으로 비만 전사 인자(adipogenic transcription factor)들의 발현이 감소하였다. In order to confirm this more specifically, according to FIG. 4 shown as a ratio, when MDI is processed to induce differentiation, the expression of the adipogenic transcription factors C/EBPα, C/EBPβ, and PPARγ is increased. However, when the ethanol extract (E1) of Sargassum horneri was treated at a concentration of 250, 500, 1,000 ㎍/ml, the expression of adipogenic transcription factors decreased in a concentration-dependent manner.
이러한 결과들을 통해 괭생이 모자반(Sargassum horneri) 에탄올 추출물(E1)은 비만 전사 인자(adipogenic transcription factor)의 발현을 억제하여 지방세포의 분화를 억제하였으며, 지방전구세포 형성과 트리글리세이드(triglyceride)의 생성을 감소하여 항비만 효과를 나타낸다는 것을 확인하였다.Based on these results, ethanol extract (E1) of Sargassum horneri inhibited the differentiation of adipocytes by suppressing the expression of adipogenic transcription factor, and the formation of adipocytes and triglycerides. It was confirmed that the anti-obesity effect was exhibited by reducing.
3. 복합 추출물의 항비만 효과 검토3. Review of anti-obesity effect of complex extract
상기 E1에 대한 항비만 효과는 실시예 1의 실험예 1 및 2에서 관련 효과를 확인하였다. 이후, E2 내지 E7에 대한 항비만 효과를 확인하기 위해 동일 실험을 진행하였으며, 그 결과는 E1에 대한 상대적인 효과로 비교하여 나타내었다. The anti-obesity effect on the E1 was confirmed in Experimental Examples 1 and 2 of Example 1. Thereafter, the same experiment was conducted to confirm the anti-obesity effect on E2 to E7, and the results were compared and shown as a relative effect on E1.
E1과 비교한 항비만 효과 확인을 위해 E1을 지수 5로 놓고, E2 내지 E7에 대한 항비만 효과를 지수 1 내지 10으로 평가하였으며, 지수가 클수록 항비만 효과가 우수함을 의미한다고 할 것이다. In order to confirm the anti-obesity effect compared to E1, E1 was set as the index 5, and the anti-obesity effect for E2 to E7 was evaluated as
상기 표 2에 나타낸 바와 같이, E1과 비교하여, E3, E4, E6 및 E7에서 동등 이상의 항비만 효과가 나타남을 확인하였다. 이는 괭생이 모자반 추출물만 사용하는 경우와 비교하여, 천연 복합 추출물로 사용 시, 각 성분간의 복합 작용에 의해 항비만 효과가 상승함을 의미한다고 할 것이다. As shown in Table 2, compared to E1, it was confirmed that the anti-obesity effect of E3, E4, E6 and E7 was equal or higher than that of E1. This would mean that the anti-obesity effect increases due to the complex action of each component when used as a natural complex extract, compared to the case of using only the extract of hoe-saeng.
[실시예 2: 관능성 실험][Example 2: Sensory test]
싱기 E1 내지 E7에 대해 관능성 실험을 진행하였다. 관능성 실험을 진행하기 위해 성인남녀 20명을 대상으로 E1 내지 E7을 차로 제조한 이후, 제공하였으며 맛, 향 및 종합 기호도를 점수로 평가해주시기를 요청하였다. Sensory experiments were conducted on the Singgi E1 to E7. In order to conduct the sensory test, E1 to E7 were prepared as teas for 20 adult men and women, and were then provided and requested to evaluate taste, aroma, and overall acceptability by scores.
점수는 1 내지 10점으로 평가를 요청하였으며, 그 결과는 평균 점수로 환산하여 하기 표 3에 나타내었다. The score was requested for evaluation with 1 to 10 points, and the results are shown in Table 3 below in terms of an average score.
상기 표 3에 나타낸 바와 같이, E1 내지 E7에서 E6 및 E7에서 맛, 향 및 기호도에서 모두 우수한 평가를 받았다. As shown in Table 3, in E1 to E7, E6 and E7 received excellent evaluations in terms of taste, flavor, and preference.
E3 및 E4의 경우, 앞서 확인한 바와 같이 항비만 효과에서 우수한 평가를 나타내었으나, 기능성 식품 조성물로 제공 시, 천연 추출물 고유의 향 및 맛으로 인해 기호도가 떨어지는 문제가 있다. E3 and E4 showed excellent evaluation in anti-obesity effect as confirmed above, but when provided as a functional food composition, there is a problem in that the palatability is poor due to the inherent aroma and taste of natural extracts.
이에, E6 및 E7의 경우, 항비만 효과에서 E3 및 E4와 비교하여 동등 또는 그 이상의 효과가 있는 것으로 확인됨과 동시에, 관능성 평가에서도 우수한 평가를 나타냄을 확인하였다.Accordingly, in the case of E6 and E7, it was confirmed that the anti-obesity effect had an effect equal to or higher than that of E3 and E4, and at the same time, it was confirmed that it showed an excellent evaluation in the sensory evaluation.
Claims (7)
낭아초(Indigofera pseudotinctoria) 추출물, 일엽초(Lepisorus thunbergianus (Kaulf.) Ching) 추출물, 곤달비(Ligularia stenocephala) 추출물, 수호초(Pachysandra terminalis) 추출물 및 나한과(Siraitia grosvenorii) 추출물을 추가로 포함하고,
지방전구세포 형성 및 트리글리세리드(triglyceride)의 생성을 감소하여 비만 예방 효과가 우수한
괭생이 모자반의 추출물을 유효성분으로 포함하는 항비만용 조성물.
It contains the extract of Sargassum horneri and its fraction as an active ingredient,
It further includes Indigofera pseudotinctoria extract, Lepisorus thunbergianus (Kaulf.) Ching) extract, Ligularia stenocephala extract, Pachysandra terminalis extract, and Siraitia grosvenorii extract,
Excellent obesity prevention effect by reducing the formation of adipocytes and triglyceride
A composition for anti-obesity comprising the extract of hoesaengi Mojaban as an active ingredient.
상기 괭생이 모자반(Sargassum horneri) 추출물은 물, C₁ 내지 C5의 저급 알코올 및 이들의 혼합물로 이루어진 군으로부터 선택된 추출 용매를 이용하여 추출하는 것인
괭생이 모자반의 추출물을 유효성분으로 포함하는 항비만용 조성물.
The method of claim 1,
The Sargassum horneri extract is extracted using an extraction solvent selected from the group consisting of water, C₁ to C 5 lower alcohols, and mixtures thereof.
A composition for anti-obesity comprising the extract of hoesaengi Mojaban as an active ingredient.
상기 추출 용매는 C₁ 내지 C5의 저급 알코올인
괭생이 모자반 추출물을 유효성분으로 포함하는 항비만용 조성물.
The method of claim 2,
The extraction solvent is a lower alcohol of C₁ to C 5
A composition for anti-obesity, comprising the extract of hoesaengyi mother and child as an active ingredient.
상기 괭생이 모자반 추출물은 비만 전사 인자(adipogenic transcription factor)의 발현을 억제하는 것인
괭생이 모자반의 추출물을 유효성분으로 포함하는 항비만용 조성물.
The method of claim 1,
The hoesaengi hatban extract inhibits the expression of an obesity transcription factor (adipogenic transcription factor)
A composition for anti-obesity comprising the extract of hoesaengi Mojaban as an active ingredient.
비만 예방용 식품 조성물.
Comprising the composition for anti-obesity according to any one of claims 1 to 4
Food composition for preventing obesity.
비만 예방 및 완화용 약학 조성물.
Comprising the composition for anti-obesity according to any one of claims 1 to 4
Pharmaceutical composition for preventing and alleviating obesity.
상기 약학 조성물은 약학적으로 허용되는 담체, 부형제 및 희석제로 이루어진 군으로부터 선택되는 것을 추가로 포함하는
비만 예방 및 완화용 약학 조성물.The method of claim 6,
The pharmaceutical composition further comprises selected from the group consisting of a pharmaceutically acceptable carrier, excipient, and diluent.
Pharmaceutical composition for preventing and alleviating obesity.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190000353A KR102180223B1 (en) | 2019-01-02 | 2019-01-02 | Anti-obesity composition comprising extract of Sargassum horneri |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190000353A KR102180223B1 (en) | 2019-01-02 | 2019-01-02 | Anti-obesity composition comprising extract of Sargassum horneri |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200084212A KR20200084212A (en) | 2020-07-10 |
| KR102180223B1 true KR102180223B1 (en) | 2020-11-18 |
Family
ID=71604071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020190000353A KR102180223B1 (en) | 2019-01-02 | 2019-01-02 | Anti-obesity composition comprising extract of Sargassum horneri |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102180223B1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220034688A (en) | 2020-09-11 | 2022-03-18 | 주식회사 제넨셀씨앤에프 | A composition for preventing or treating obesity and atherosclerosis comprising Galla Rhois ethanol extract as active ingredient |
| KR20230111381A (en) | 2022-01-18 | 2023-07-25 | 선문대학교 산학협력단 | A composition for improving, preventing and treating of obesity comprising Sargassum horneri Turner C. Agardh extract |
| KR102438276B1 (en) * | 2022-06-20 | 2022-08-30 | 주식회사 제주바이오테크 | Anti-inflammatory and anti-obesity composition comprising Sargassum horneri extract and method for preparing the same |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6360357B2 (en) * | 2014-03-24 | 2018-07-18 | 株式会社マルハチ村松 | Method for inhibiting adipocyte formation |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140083493A (en) | 2012-12-26 | 2014-07-04 | 대한민국(관리부서:국립수산과학원) | Composition for anti-obesity comprising extract of Sargassum fulvellum or Sargassum horneri as an effective component |
-
2019
- 2019-01-02 KR KR1020190000353A patent/KR102180223B1/en active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6360357B2 (en) * | 2014-03-24 | 2018-07-18 | 株式会社マルハチ村松 | Method for inhibiting adipocyte formation |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200084212A (en) | 2020-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102180223B1 (en) | Anti-obesity composition comprising extract of Sargassum horneri | |
| KR101874462B1 (en) | Composition for preventing, ameliorating or treating atopic dermatitis comprising Schisandra chinensis leaf extract as effective component | |
| KR102011684B1 (en) | Extracts of the mori folium having immunity enhancing activity and a method for producing the same | |
| KR102094001B1 (en) | An anti-obesity composition comprising Gelidium amansii extract and Salicornia europaea extract | |
| KR102305931B1 (en) | A food composition for improving circulation of blood and increasing functions of immune comprising natural extracts | |
| KR102302933B1 (en) | Preparation of fermented garlic mixture and manufacturing method of composition effective for cardiovascular disease | |
| KR102139732B1 (en) | Composition for improving immune activity containing lactobacillus | |
| TWI734322B (en) | Kimchi for prevention or treatment of disease related to helicobacter pylori | |
| KR20180042936A (en) | a composition comprising the mycelium culture medium from Schizophyllum commune as an active ingredient for preventing or treating liver disease and alleviating hangover | |
| KR20160079269A (en) | Anti-inflammatory pharmaceutical composition and health functional food containing artemisia fermentation extract | |
| KR20200053016A (en) | Pharnaceutical composition for prevention or treatment of diabetes comprising the mixed extract of vegetable natural products having the effect on removal of swelling and health functional food for prevention or improvement of diabetes comprising the same | |
| KR20190137317A (en) | Composition comprising carpomitra costata(stackhouse) batters extract for preventing or treating osteoarthritis | |
| KR20150072660A (en) | Hepatoprotective composition containing adenophora triphylla extract | |
| KR102064516B1 (en) | An antibacterial composition comprising an leaf and root extract of cudrania tricuspidata, and extract of licorice | |
| KR102131925B1 (en) | Composition for Preventing or Treating Mental Disorder | |
| KR102342814B1 (en) | Composition containing an fermented extract of protaetia brevitarsis seulensis as an active ingredient and manufacturing the same | |
| KR101525877B1 (en) | A composition for preventing wrinkle of skin and anti aging of skin | |
| KR102552886B1 (en) | Composition for preventing and improving obesity, and functional food containing the same | |
| KR101344564B1 (en) | Composition comprising extract of hot peppers and Chinese peppers for preventing or treating of obesity or hyperlipidemia | |
| KR102337130B1 (en) | Composition comprising fermented Oriental medicine herbs for preventing, improving or treating obesity, and method for preparing the same | |
| KR20150072659A (en) | Hepatoprotective composition containing smilax china extract | |
| JP7297362B2 (en) | Food composition containing placenta extract and ginseng seed extract | |
| KR102542119B1 (en) | Composition for preventing or treating inflammatory airway diseases caused fine dust comprising syneilesis aconitifolia (bunge) maxim extract | |
| KR20190103665A (en) | Food composition for improving or preventing obesity containing extract of saururus chinensis | |
| KR102611957B1 (en) | Composition for preventing or treating muscular disease comprising syneilesis aconitifolia (bunge) maxim extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |